mortality/aging
|
• small but significant increase in mortality by 18 months
|
hematopoietic system
anisocytosis
(
J:41621
)
|
• variable red blood cell size
|
|
• high levels of reticulocytes in peripheral blood, up to 30%
• severity of reticulocytosis increases with age
|
|
• increase as kidney disease develops
|
|
• increased numbers of erythroblasts in bone marrow
|
|
• elevated erythroid precursors
• lymphoid tissues are otherwise normal
|
|
• marked splenomegaly at all ages examined
|
|
• reduced osmotic fragility
|
renal/urinary system
|
• an expanded mesangial matrix often causes obstruction of capillary lumina
|
|
• in more than 80% of homozygotes at 12 months of age
• elevated Ig and C3 deposition in kidney glomeruli by 6 months
• frequently elevated mononuclear leukocyte infiltrates
|
|
• extensive scarring of the kidneys develops
|
|
• normal to at least 3 months of age
|
|
• low or moderate
• in about 30% of homozygotes
|
liver/biliary system
|
• mononuclear leukocyte infiltrates are frequently elevated
|
respiratory system
|
• mononuclear leukocyte infiltrates are frequently elevated
|
immune system
| N |
• B and T cell development and function normal
(J:74579)
|
|
• increase as kidney disease develops
|
|
• elevated erythroid precursors
• lymphoid tissues are otherwise normal
|
|
• marked splenomegaly at all ages examined
|
|
• circulating immune complexes become elevated
|
|
• starting at 10 weeks of age
|
|
• starting at 10 weeks of age
|
|
• starting at 10 weeks of age
|
|
• antinuclear antibody in about 60% of mice having hematuria
|
|
• mononuclear leukocyte infiltrates are frequently elevated
|
|
• in more than 80% of homozygotes at 12 months of age
• elevated Ig and C3 deposition in kidney glomeruli by 6 months
• frequently elevated mononuclear leukocyte infiltrates
|
|
• mononuclear leukocyte infiltrates are frequently elevated
|
homeostasis/metabolism
|
• low or moderate
• in about 30% of homozygotes
|
Mouse Models of Human Disease |
OMIM ID | Ref(s) | |
| Anemia, Dyserythropoietic Congenital, Type II; CDAN2 | 224100 | J:41621 | |
| Systemic Lupus Erythematosus; SLE | 152700 | J:74579 | |
